Brown RD - Search Results

1

Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: results from the MRC (UK) V trial.

Brown RD, Joshua DE, Nelson M, Gibson J, Dunn J, MacLennan IC. Brown RD, et al. Br J Haematol. 1993 Jun;84(2):238-41. doi: 10.1111/j.1365-2141.1993.tb03058.x. Br J Haematol. 1993. PMID: 8398824 Clinical Trial.

2

Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma.

Brown R, Murray A, Pope B, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D. Brown R, et al. Br J Haematol. 2004 Jun;125(6):743-8. doi: 10.1111/j.1365-2141.2004.04984.x. Br J Haematol. 2004. PMID: 15180863 Free article.

3

Idiotypic oligonucleotide probes to detect myeloma cells by mRNA in situ hybridization.

Brown R, Luo XF, Gibson J, Morley A, Sykes P, Brisco M, Joshua D. Brown R, et al. Br J Haematol. 1995 May;90(1):113-8. doi: 10.1111/j.1365-2141.1995.tb03388.x. Br J Haematol. 1995. PMID: 7786772

4

The labelling index of primitive plasma cells determines the clinical behaviour of patients with myelomatosis.

Joshua D, Petersen A, Brown R, Pope B, Snowdon L, Gibson J. Joshua D, et al. Br J Haematol. 1996 Jul;94(1):76-81. doi: 10.1046/j.1365-2141.1996.d01-1784.x. Br J Haematol. 1996. PMID: 8757512

5

Measurement of free kappa and lambda chains in serum and the significance of their ratio in patients with multiple myeloma.

Nelson M, Brown RD, Gibson J, Joshua DE. Nelson M, et al. Among authors: brown rd. Br J Haematol. 1992 Jun;81(2):223-30. doi: 10.1111/j.1365-2141.1992.tb08211.x. Br J Haematol. 1992. PMID: 1643019

6

Serum thymidine kinase as a marker of disease activity in patients with multiple myeloma.

Brown RD, Joshua DE, Ioannidis RA, Kronenberg H. Brown RD, et al. Aust N Z J Med. 1989 Jun;19(3):226-32. doi: 10.1111/j.1445-5994.1989.tb00251.x. Aust N Z J Med. 1989. PMID: 2528340

7

Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression.

Wearne AJ, Joshua DE, Brown RD, Kronenberg H. Wearne AJ, et al. Among authors: brown rd. Br J Haematol. 1987 Sep;67(1):39-44. doi: 10.1111/j.1365-2141.1987.tb02293.x. Br J Haematol. 1987. PMID: 2959309

8

Multiple myeloma: why does the disease escape from plateau phase?

Joshua DE, Brown RD, Gibson J. Joshua DE, et al. Among authors: brown rd. Br J Haematol. 1994 Dec;88(4):667-71. doi: 10.1111/j.1365-2141.1994.tb05102.x. Br J Haematol. 1994. PMID: 7819092 Review. No abstract available.

9

Prognostic factors in myeloma: what they tell us about the pathophysiology of the disease.

Joshua DE, Brown RD, Gibson J. Joshua DE, et al. Among authors: brown rd. Leuk Lymphoma. 1994 Nov;15(5-6):375-81. doi: 10.3109/10428199409049739. Leuk Lymphoma. 1994. PMID: 7873994 Review.

10

Mechanisms of the escape phase of myeloma.

Joshua DE, Gibson J, Brown RD. Joshua DE, et al. Among authors: brown rd. Blood Rev. 1994 Mar;8(1):13-20. doi: 10.1016/0268-960x(94)90003-5. Blood Rev. 1994. PMID: 8205006 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

986 results

Search Page

Filters